Financials in USD. Standardized financial statements.
A compact view of how Mirum Pharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue? | $521.31M | $336.89M | $186.37M | $77.06M | $19.14M | $0 | $0 | $0 |
| Revenue Growth? | +54.7% | +80.8% | +141.8% | +302.7% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $100.58M | $81.64M | $47.04M | $12.37M | $1.90M | $623,000 | $324,000 | $0 |
| Gross Profit? | $420.73M | $255.25M | $139.34M | $64.69M | $17.23M | -$623,000 | -$324,000 | $0 |
| Gross Margin? | +80.7% | +75.8% | +74.8% | +83.9% | +90.1% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $443.21M | $342.85M | $248.49M | $195.91M | $190.65M | $103.67M | $54.74M | $2.92M |
| Operating Income? | -$22.14M | -$87.61M | -$109.15M | -$131.22M | -$173.41M | -$104.30M | -$54.74M | -$2.92M |
| EBITDA? | $17.21M | -$48.97M | -$136.49M | -$122.85M | -$65.39M | -$102.31M | -$52.21M | -$17.33M |
| Income Before Tax | -$21.43M | -$86.91M | -$162.42M | -$142.07M | -$83.95M | -$103.26M | -$52.53M | -$17.35M |
| Income Tax Expense | $1.94M | $1.03M | $991,000 | -$6.41M | $37,000 | $6,000 | $21,000 | $0 |
| Net Income? | -$23.36M | -$87.94M | -$163.41M | -$135.66M | -$83.99M | -$103.27M | -$52.55M | -$17.35M |
| EPS? | $-0.47 | $-1.85 | $-4.00 | $-4.01 | $-2.77 | $-4.09 | $-2.29 | $-0.75 |
| Diluted EPS? | $-0.47 | $-1.85 | $-4.00 | $-4.02 | $-2.77 | $-4.09 | $-2.29 | $-0.75 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality